Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 26, 2019 16:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., July 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention
July 11, 2019 08:00 ET
|
Alder BioPharmaceuticals, Inc.
- Posters presented at the 2019 American Headache Society meeting highlight eptinezumab’s safety profile and suppression of calcitonin gene-related peptide (CGRP) - - New data...
Alder BioPharmaceuticals® to Showcase 14 New Data Presentations Demonstrating Eptinezumab’s Migraine Prevention and Quality of Life Impact at American Headache Society Meeting
July 08, 2019 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., July 08, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Webcast Upcoming Breakfast Symposium with Key Opinion Leaders
June 19, 2019 08:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., June 19, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at BMO Capital Markets 2019 Prescription for Success Healthcare Conference
June 18, 2019 16:01 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., June 18, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2019 16:05 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., May 24, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at Two Upcoming May Investor Conferences
May 14, 2019 16:05 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., May 14, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention
May 08, 2019 08:00 ET
|
Alder BioPharmaceuticals, Inc.
- Data presented at the 2019 American Academy of Neurology (AAN) meeting demonstrate nearly 60% of patients reported very much or much improvement in most bothersome symptoms and in overall migraine...
Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials
May 06, 2019 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., May 06, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Reports First Quarter 2019 Financial and Operating Results
May 02, 2019 16:05 ET
|
Alder BioPharmaceuticals, Inc.
- FDA sets eptinezumab PDUFA date of February 21, 2020; launch expected in first quarter of 2020 - - Acute study planned for potential eptinezumab label expansion - -...